Veteran launch leaders explain why data abundance is making launches harder and what the new operating model actually requires

Integrating data, operations and digital capabilities creates a seamless customer experience across touchpoints 

How pharmaceutical companies can leverage artificial intelligence to create more human-centered experiences for healthcare professionals and patients 

How Astellas is revolutionizing commercialization by embracing agility and continuous customer feedback 
 

Pharmaceutical leaders highlight how AI is enhancing patient outcomes through personalized engagement, improved data insights, and streamlined operations

Industry leaders from Novartis, Bayer, and Tellius reveal how generative AI and agentic workflows are delivering real-world value across commercial operations.

Shifting focus from transactional acquisition to holistic customer lifecycle management creates new domains of competition and differentiation.

Transforming Industry Speed Through Talent and Mindset

As targeted therapies transform cancer treatment, industry must shift focus to education to ensure patients don't fall through the diagnostic cracks.

Leveraging advanced technologies to drive personalized customer experiences and improved health outcomes 

Leveraging innovation, generative AI, and strategic collaboration to drive business success and unlock new opportunities in the pharmaceutical industry.

In a world where misinformation moves faster than facts, pharmaceutical companies must engage patients authentically where they already gather information.

Innovative approaches to disease prevention are transforming healthcare delivery and patient outcomes

Embracing change and driving innovation to improve patient outcomes and transform the pharmaceutical industry.

How pharma leaders are using technology to solve real patient problems and drive adherence through personalization and participation.

How pharma can develop effective digital health strategies by focusing on patient needs rather than technology-first approaches.

Understanding business objectives, embracing agile approaches, and focusing on patient impact creates lasting partnerships that transform digital health globally.

Harnessing research and evidence to shape healthcare policies that ensure patient access, affordability, and innovation.

Combining wearable technology, patient surveys, and traditional healthcare records creates a comprehensive view of health journeys that can drive better outcomes and research opportunities.

Leveraging data-driven insights to accelerate innovation, improve patient outcomes, and revolutionize the future of healthcare

Industry leaders from AstraZeneca, Bayer, and Soleno reveal how integrated data strategies and AI-powered insights are transforming pharma's ability to reach patients and providers at critical decision moments.

The Urgent Need for Early, Accessible Detection has been recognised at the Reuters Events Global Pharma Awards 2025, for Most Valuable Breakthrough/Discovery Award

At the Reuters Events Global Pharma Awards 2025, this project demonstrated the importance of collaboration, winning the category for Most Valuable Collaboration Award

Pfizer’s project is the winner of the Health Equity Award at the Reuters Events Global Pharma Awards 2025

A Johnson & Johnson initiative has been awarded the winner of Valuable Medical Education/Awareness Initiative Award at the Reuters Events Global Pharma Awards

Find out more about the winning project of the Patient Champion Award at the Reuters Events Global Pharma Awards 2025

Discover more about VeriSIM Life’s project as winners of the AI in Action Award at the Reuters Events Global Pharma Awards

Find out more about the winner of the Sustainability Initiative of the Year Award category at the Reuters Events Global Pharma Awards 2025

A deep dive into how ecosystem design, early multi-stakeholder engagement, and AI-powered responsiveness are replacing fragmented touchpoints with unified customer journeys.

Aithena co-founders reveal how AI-powered MLR systems deliver 90% review time reductions while maintaining compliance quality and accountability.

Bayer's Field Medical Excellence Director & Global Lead, Saurabh Dayal, reveals how mindset transformation and joint training unlock seamless medical-commercial collaboration across global markets.

AstraZeneca research reveals how conversational AI addresses HCP information overload while achieving 200% engagement increases through strategic implementation.

Industry leaders tackle the critical disconnect between pharma's engagement confidence and HCP satisfaction, revealing why field force transformation is no longer optional.

Simone Rebora, reveals why 80% of failed pharma launches never recover and how fixing the basics before deploying AI transforms global customer engagement.

CSL Vifor's marketing mix modeling (MMM) revealed how reallocating promotional spend from field-heavy tactics to high-ROI digital channels delivered 10% sales growth during loss of exclusivity (LOE)—without increasing budget.

Sumitomo Pharma executives reveal how integrated regulatory-commercial strategy and comprehensive patient support transformed RETHYMIC from Complete Response Letter to sustained market success

Pharma executive and patient advocates reveal why rare disease access demands multi-stakeholder engagement beyond traditional HCP focus

Evidence-based marketing research reveals that penetration, not loyalty, drives sustainable pharma growth—validated across therapeutic areas and practitioner experience.

aLeading pharma strategists challenge industry orthodoxy on measurement, content activation, and field force evolution

How breaking down organizational silos, orchestrating cross-functional collaboration, and shifting from push to pull strategies can transform customer-centricity from aspiration to operational reality

Takeda analytics leaders showcase how their innovative, internally-built AI platform is transforming their approach to research by unlocking previously untapped insights and accelerating impact across multiple therapeutic areas.

How generative AI is reshaping search behavior and why pharma marketers must optimize content for LLM visibility now.

Haider Alleg General Partner Allegory Capital

Industry leaders from Sandoz, GSK, Syneos Health and ViiV Healthcare reveal why only 5% of AI pilots scale, and what separates experimentation from enterprise impact.

Speaker: Karl Moritz Hermann, CEO, Reliant AI

When Egis Pharma began evaluating CRM vendors, they faced a complexity paradox that haunts mid-sized pharma companies

Mark Ralphs, Digital Strategy and Experience Lead, Publicis Health UK & Head of Strategy, Digitas Health LDN

Performance.io executives challenge pharma's digital waste while providing a reality check on AI investments and consolidated search strategies that rebuild patient trust.

How Accenture, Astellas and BioMarin are breaking organizational silos and deploying AI to transform customer engagement from brand-centric campaigns to real-time, personalized journeys.

How early patient integration, data transparency, and addressing invisible patient populations are reshaping commercial strategy.

The pharma industry faces a productivity paradox: artificial intelligence demonstrates transformative potential, particularly in pilots, yet bottom-line impact remains elusive.

The final panel at Clinical Innovation 2025 opened with a pointed observation: everyone remaining in the room had chosen to stay for a conversation about trust rather than head to cocktails

Clinical trial site selection remains one of the pharma industry's most expensive guessing games.

How orchestration architecture and compliance-first design are transforming pharma content operations from months-long workflows to intelligent, cross-platform systems.

"Optichannel" approach delivers 24% prescription lift while reducing spend through real-time data, trigger-based targeting, and machine learning optimization

The clinical trial graveyard for Alzheimer's disease contains dozens of small biotechs with novel mechanisms that never survived their first efficacy failure

PwC strategists outline the data foundations, business discipline, and ecosystem thinking required to transform pharma CRM from static segmentation to AI-powered real-time personalization

Medical affairs leaders reveal how co-creation with diverse stakeholders transforms content relevance and patient outcomes across therapeutic areas.

The pharma industry faces an uncomfortable truth: financial constraints force systematic compromises in monitoring quality that directly put trial outcomes at risk. Traditional central review approaches examine 100% of screening and baseline assessments but that scrutiny can reduce to 20% random sample at follow up visits, leaving the majority of rater patient interactions completely unreviewed.

Why pharma's hard-won governance maturity doesn't transfer to the next AI generation — and what the people working for the fastest running organizations feel is best instead.

Pharma's evidence capabilities have outpaced institutional readiness—manufacturers closing that gap before launch are defining the next access advantage.

Post-launch performance insights reveal that many launches underperform despite strong product profiles

Pharma's most rigorous evidence is invisible to LLMs - and the internal platforms built for launch speed may hold the fix no one has framed yet.

Finding patients, rebuilding physician education from scratch, and rethinking what "access" actually means in rare disease

Why pharma struggle with scaling AI and why the barrier is organizational architecture, not technology

Nine-figure payer deals pass financial modeling without a basic commercial feasibility test

Why the foundational layer organizations are most tempted to skip is the only barrier between deployment and irreversible user abandonment

Physician AI copilot data shows that passive, hard-to-reach doctors respond best when outreach is triggered by real-time clinical intent

Pharma spends $20 billion annually on content most HCPs never see, so how do we fix this?

The real bottleneck is not AI generation power but structuring and activating the data that is sitting inside pharma's information systems

Pharma's field excellence gap is self-inflicted, and the organizations pulling ahead share one trait: the discipline to stop doing things

Physician adoption tails stretch seven years in oncology. Here's what predictive intelligence can do about it.

Pharma's AI deployments are hardening the functional silos they were meant to dissolve. The operating model and culture must come first.

Does your forecasting organization start with the goal or is it still searching for it?

AI is dissolving pharma's information advantage over HCPs and the companies still optimizing their engagement model haven't noticed yet

Pharma is retreating from HCP engagement at the exact moment AI intermediaries and practicing clinicians are making that presence more valuable than ever.

When budgets shrink and loss of exclusivity looms, the brands that survive aren't managed differently, they're led differently.

Western pharma's rational retreat from European launches may be building the market entry for the competitors best positioned to replace them

Why adding reps cannot close pharma's coverage gap and how compliance infrastructure becomes the unlikely enabler of AI-driven commercial scale.